{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Chronic GVHD that meets NIH criteria"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"No documented chronic GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Chronic GVHD measured by meeting NIH criteria and treated with immune suppression","groups":[{"description":"CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC and tacrolimus for GVHD prophylaxis","id":"OG000","title":"Overall Study Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants alive and without relapse at D100","reportingStatus":"POSTED","timeFrame":"Up to 5 years post transplant","title":"Number of Participants With Chronic GVHD","type":"SECONDARY","unitOfMeasure":"Participants"}